Rosuvastatin Affecting Aortic Valve Endothelium
|Study Design:||Observational Model: Defined Population
Observational Model: Natural History
Time Perspective: Longitudinal
Time Perspective: Prospective
|Official Title:||Rosuvastatin Affecting Aortic Valve Endothelium - RAAVE|
|Study Start Date:||September 2003|
|Estimated Study Completion Date:||May 2005|
Background: Recent retrospective studies support the hypothesis that statins slow the progression of aortic stenosis. The aim of this study was to assess the effect of Rosuvastatin on hemodynamic progression of aortic stenosis by treating patients with aortic stenosis and elevated LDL-cholesterol for 18 months.
Methods: We performed an open-label, prospective study evaluating 121 consecutive patients with asymptomatic moderate to severe aortic stenosis (AVA≥ 1.0 cm2), (mean age 73.7±8.9 years; 57 men and 64 women), treated with and without Rosuvastatin according to the NCEP-ATPIII guidelines. Echocardiographic, serum lipid, and inflammatory markers were measured at baseline and every 6 months for 18 months.
Please refer to this study by its ClinicalTrials.gov identifier: NCT00114491
|Hospital Pedro Hispano|
|Principal Investigator:||Luis M Moura||Hospital Pedro Hispano|